Retinoblastoma seeds: impact on American Joint Committee on Cancer clinical staging.


Journal

The British journal of ophthalmology
ISSN: 1468-2079
Titre abrégé: Br J Ophthalmol
Pays: England
ID NLM: 0421041

Informations de publication

Date de publication:
01 2023
Historique:
received: 21 01 2021
accepted: 10 07 2021
pubmed: 4 8 2021
medline: 20 12 2022
entrez: 3 8 2021
Statut: ppublish

Résumé

To investigate whether the American Joint Committee on Cancer (AJCC) clinical category cT2b needs to be subclassified by the type and distribution of retinoblastoma (RB) seeding. Multicentre, international registry-based data were collected from RB centres enrolled between January 2001 and December 2013. 1054 RB eyes with vitreous or subretinal seeds from 18 ophthalmic oncology centres, in 13 countries within six continents were analysed. Local treatment failure was defined as the use of secondary enucleation or external beam radiation therapy (EBRT) and was estimated with the Kaplan-Meier method. Clinical category cT2b included 1054 eyes. Median age at presentation was 16.0 months. Of these, 428 (40.6%) eyes were salvaged, and 430 (40.8%) were treated with primary and 196 (18.6%) with secondary enucleation. Of the 592 eyes that had complete data for globe salvage analysis, the distribution of seeds was focal in 143 (24.2%) and diffuse in 449 (75.8%). The 5-year Kaplan-Meier cumulative globe-salvage (without EBRT) was 78% and 49% for eyes with focal and diffuse RB seeding, respectively. Cox proportional hazards regression analysis confirmed a higher local treatment failure risk with diffuse seeds as compared with focal seeds (hazard rate: 2.8; p<0.001). There was insufficient evidence to prove or disprove an association between vitreous seed type and local treatment failure risk(p=0.06). This international, multicentre, registry-based analysis of RB eyes affirmed that eyes with diffuse intraocular distribution of RB seeds at diagnosis had a higher risk of local treatment failure when compared with focal seeds. Subclassification of AJCC RB category cT2b into focal vs diffuse seeds will improve prognostication for eye salvage.

Identifiants

pubmed: 34340974
pii: bjophthalmol-2021-318892
doi: 10.1136/bjophthalmol-2021-318892
pmc: PMC9205754
mid: NIHMS1814232
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

127-132

Subventions

Organisme : NCI NIH HHS
ID : K08 CA232344
Pays : United States

Investigateurs

Sarah E Coupland (SE)
Daniel M Albert (DM)
Anush G Amiryan (AG)
Svetlana Saakyan (S)
Claudia Auw-Hädrich (C)
Diane Baker (D)
Raymond Barnhill (R)
José M Caminal (JM)
William L Caroll (WL)
Nathalie Cassoux (N)
Laurence G Desjardins (LG)
François Doz (F)
Gaelle Pierron (G)
Patricia Chévez-Barrios (P)
R Max Conway (R)
Bertil E Damato (BE)
Hakan Demirci (H)
Jonathan J Dutton (JJ)
Bita Esmaeli (B)
Victor G Prieto (VG)
Michelle Williams (M)
Brenda L Gallie (BL)
Gerardo F Graue (GF)
Hans E Grossniklaus (HE)
Steffen Heegaard (S)
Leonard M Holbach (LM)
Santosh G Honavar (SG)
Martine J Jager (MJ)
Emma Kujala (E)
Livia Lumbroso-Le Rouic (LL)
Giulio M Modorati (GM)
Francis L Munier (FL)
Timothy G Murray (TG)
Anna C Pavlick (AC)
Jacob Pe'er (J)
David E Pelayes (DE)
Manuel Jorge Rodriguez (MJ)
Wolfgang Ag Sauerwein (WA)
Stefan Seregard (S)
Carol Shields (C)
E Rand Simpson (E)
Arun D Singh (AD)
Shigenobu Suzuki (S)
Mary Kay Washington (MK)
Valerie A White (VA)
Mathew W Wilson (MW)
Christian W Wittekind (CW)
Vivian Yin (V)

Informations de copyright

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Ankit Singh Tomar (AS)

Department of Ocular Tumor and Orbital Disease, New York Eye Cancer Center, New York, New York, USA.

Paul T Finger (PT)

Department of Ocular Tumor and Orbital Disease, New York Eye Cancer Center, New York, New York, USA pfinger@eyecancer.com.

Brenda Gallie (B)

The Eye Cancer Clinic, Princess Margaret Cancer Centre, and Department of Ophthalmology and Vision Sciences, Hospital for Sick Children, Toronto, Ontario, Canada.

Tero Kivelä (T)

Ocular Oncology Service, Department of Ophthalmology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Ashwin Mallipatna (A)

Department of Ophthalmology and Vision Sciences, Hospital for Sick Children, Toronto, Ontario, Canada.
Department of Ophthalmology and Vision Sciences, Narayana Nethralaya, Bangalore, Karnataka, India.

Chengyue Zhang (C)

Pediatric Oncology Center, Beijing Children's Hospital, Beijing, China.

Junyang Zhao (J)

Pediatric Oncology Center, Beijing Children's Hospital, Beijing, China.

Matthew Wilson (M)

Ophthalmic Oncology, Department of Ophthalmology Hamilton Eye Institute, The University of Tennessee Health Science Center, Memphis, Tennessee, USA.

Rachel Brennan (R)

Department of Ophthalmology, St Jude Children's Research Hospital, Memphis, Tennessee, USA.

Michala Burges (M)

Ophthalmic Oncology, Department of Ophthalmology Hamilton Eye Institute, The University of Tennessee Health Science Center, Memphis, Tennessee, USA.

Jonathan Kim (J)

USC Roski Eye Institute, Keck Medical School of the University of Southern California, and The Vision Center at Children's Hospital Los Angeles, Los Angeles, California, USA.

Jesse L Berry (JL)

Department of Pediatrics, Children's Hospital Los Angeles, Los Angeles, California, USA.

Rima Jubran (R)

Cancer and Blood Diseases, Childrens Hospital Society of Los Angeles, Los Angeles, California, USA.

Vikas Khetan (V)

Vitreo Retinal Services, Sankara Nethralaya, Chennai, Tamil Nadu, India.

Suganeswari Ganeshan (S)

Vitreo Retinal Services, Sankara Nethralaya, Chennai, Tamil Nadu, India.

Andrey Yarovoy (A)

Ocular Oncology Department, S Fyodorov Eye Microsurgery Federal State Institution, Moskva, Moskva, Russian Federation.

Vera Yarovaya (V)

Ocular Oncology Department, S Fyodorov Eye Microsurgery Federal State Institution, Moskva, Moskva, Russian Federation.

Elena Kotova (E)

Ocular Oncology Department, S Fyodorov Eye Microsurgery Federal State Institution, Moskva, Moskva, Russian Federation.

Denis Volodin (D)

Ocular Oncology Department, S Fyodorov Eye Microsurgery Federal State Institution, Moskva, Moskva, Russian Federation.

Yacoub Yousef (Y)

Department of Surgery (Ophthalmology), King Hussein Cancer Center, Amman, Jordan.

Kalle Nummi (K)

Ocular Oncology Service, Department of Ophthalmology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Tatiana L Ushakova (TL)

Pediatric Oncology and Hematology, N N Blokhin NMRCO, Moskva, Russian Federation.
Russian Academy of Postgraduate Medical Education, Moskva, Russian Federation.

Olga V Yugay (OV)

Pediatric Oncology and Hematology, N N Blokhin NMRCO, Moskva, Russian Federation.

Vladimir G Polyakov (VG)

Pediatric Oncology and Hematology, N N Blokhin NMRCO, Moskva, Russian Federation.
Russian Academy of Sciences, Moskva, Russian Federation.

Marco Antonio Ramirez-Ortiz (MA)

Department of Ophthalmology, Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico.

Elizabeth Esparza-Aguiar (E)

Department of Ophthalmology, Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico.

Guillermo L Chantada (GL)

Ophthalmology, Paediatric Hospital Dr Juan Garrahan Library, Buenos Aires, Argentina.

Paula Schaiquevich (P)

Precision Medicine Coordination Hospital J. P. Garrahan, and CONICET (National Scientific and Technical Research Council), Buenos Aires, Argentina.

Adriana C Fandiño (AC)

Ophthalmology, Paediatric Hospital Dr Juan Garrahan Library, Buenos Aires, Argentina.

Jason C Yam (JC)

Opthamology and Visual Sciences, The Chinese University of Hong Kong Faculty of Medicine, Hong Kong, Hong Kong.

Winnie W Lau (WW)

Department of Ophthalmology and Visual Sciences, Hong Kong Eye Hospital, Hong Kong, Hong Kong.

Carol P Lam (CP)

Department of Ophthalmology and Visual Sciences, Hong Kong Eye Hospital, Hong Kong, Hong Kong.

Phillipa Sharwood (P)

Save Sight Institute, Discipline of Ophthalmology, The University of Sydney Sydney Medical School, Sydney, New South Wales, Australia.

Sonia Moorthy (S)

Retinoblastoma Unit, Department of Oncology, Hospital Sant Joan de Déu. Esplugues de Llobregat, Barcelona, Spain.

Quah Boon Long (QB)

KK Women's and Children's Hospital, Singapore.

Vera Adobea Essuman (VA)

Department of Child Heath, University of Ghana Medical School, Accra, Ghana.

Lorna A Renner (LA)

Department of Child Health, University of Ghana Medical School, Accra, Greater Accra, Ghana.

Ekaterina Semenova (E)

Department of Ocular Tumor and Orbital Disease, New York Eye Cancer Center, New York, New York, USA.

Jaume Català-Mora (J)

Ophthalmology, Hospital Sant Joan de Deu, Barcelona, Catalunya, Spain.

Maria Correa Llano (M)

Ophthalmology, Hospital Sant Joan de Deu, Barcelona, Catalunya, Spain.

Elisa Carreras (E)

Ophthalmology, Hospital Sant Joan de Deu, Barcelona, Catalunya, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH